Webcast scheduled for Thursday, Dec. 9 at 11:00 a.m. Eastern Time CARLSBAD, Calif. , Dec. 2, 2021 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a virtual investor day on Thursday, December 9 th at 11:00 a.m. Eastern Time .

– Study met its primary endpoint, achieving statistically significant reduction in non-high density lipoprotein cholesterol (non-HDL-C) compared to placebo at all doses tested – Key secondary endpoints were met including statistically significant reductions in triglycerides and angiopoietin-like-3

– OASIS-HAE is the registrational study in Ionis’ donidalorsen Phase 3 clinical program and further expands Ionis’ late-stage pipeline – Donidalorsen is one of Ionis’ wholly owned medicines the company plans to commercialize CARLSBAD, Calif. , Nov. 18, 2021 /PRNewswire/ — Ionis Pharmaceuticals,

– New data to be presented from multiple ascending dose study for Ionis’ novel antisense medicine targeting PCSK9 – Data on the effect of olezarsen on a variety of lipoprotein fractions in patients with hypertriglyceridemia to be presented – Ionis to host symposium on lessening the disproportionate

CARLSBAD, Calif. , Nov. 9, 2021 /PRNewswire/ —  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in virtual fireside chats at the following virtual investor conferences:     Stifel 2021 Healthcare Conference on Monday, November 15, 2021 Evercore ISI 4 th